附件4(a)(ii)
注册人的证券登记描述
1934年证券交易所法第12条
1934年证券交易所法第12条
康姆泰克通讯公司（“我们”，“我们的”或“公司”）在1934年修订的证券交易所法第12条下注册了一类证券：我们的普通股，每股面值0.10美元（“普通股”）。
股本结构描述
我们的股本概述仅供参考，并非完整内容。其完整性需参阅我们的修订公司章程（我们称之为“章程”），我们的b-2系列可转换优先股的指定证书（“指定证书”），我们的第三次修订公司章程（“章程”），以及特定的特拉华州通用公司法（“DGCL”）条款所限定。章程、指定证书和章程均作为年度10-k表格的附件包含在内，而本文件亦为其中的一部分。由于以下内容仅为概要，不包含所有可能对您重要的信息。若需要完整内容，请参阅章程、指定证书和章程。
总体来说
我们的章程授权发行1亿股普通股，每股面值0.10美元，并授权发行200万股优先股，每股面值0.10美元。
普通股
本次募集后，截至 2024 年 5 月 17 日，已发行普通股 1,702,226 股（包括 115,792 股未获得限制性股票奖励的股票）。截至2024年10月23日，我们共发行并流通着28,866,682股普通股。
表决权。我们的普通股股东每持有一股普通股，在所有股东投票时都有一票。
分红权。 我们的普通股股东有权在我们的董事会宣布时，按现金或财产，包括公司证券的形式，从公司资产中取得可供合法使用的分红派息。
清算权。 我们的普通股股东有权在公司清算、解散或清算后，在偿还或为我们的债务和任何未偿付的优先股股东的清算优先权后，按比例分享所有可分配给股东的剩余资产。
优先购买权。普通股股东没有优先购买、认购或其他取得公司未发行或库藏股份或其他证券的权利。
优先股
如下更详细地讨论，根据我们的章程，我们有权发行最多2,000,000股优先股。目前已指定了我们的两个系列优先股：(1) 200,000股被指定为A系列初级参与累积优先股，目前尚未发行；(2) B-2可转换优先股，其中175,263.58股目前已发行。
1
空白支票优先股。我们的公司法证书授权董事会可以随时从一个或多个系列中发行高达1亿股优先股，无需经过股东的任何进一步投票或行动，并且对于每个这样的系列，可以确定构成该系列的股份数、该系列股票的名称、权力（包括表决权）、特权及相关权利，包括相对参与、选择或其他权利和任何资格、限制或限制。发行这样的优先股可能会阻止潜在的收购提议，并可能延迟或阻止控制权的变更。根据我们的章程，我们的董事会有权在不经股东批准的情况下指定一项或多项优先股系列，发行该系列优先股的股份数，直至授权的该系列优先股的最大股份数，并确定任何该等系列的偏好、权利、特权、资格、限制和条件，包括构成任何该等系列的股份数量和此类系列的指定、红利权利、表决权利、转换权利条款、赎回权利条款、任何沉没基金、养老基金或购买基金的条件、清算优先权。在此授权下行事，我们的董事会可以指定并发行一系列具有偏好、权利、特权、资格、限制的优先股，或采纳股东权益计划，其效果是因此股东对我们的普通股拥有益处或开始提出对我们大量普通股的要约收购，而歧视现有或潜在证券持有人。授权但未发行和未保留的股权有一种效果可能会使潜在收购者试图通过合并、要约收购、代理选举或其他方式获得对公司的控制变得更加困难或阻止，从而保护公司管理的连续性。发行此类股权可能会延迟、推迟或阻止公司控制权的变更，无须我们的股东采取任何进一步行动。我们目前没有采用股东权益计划的意图，但在任何将来时间可以在不经股东批准的情况下这样做。
A系列优先累积优先股。 截至2024年10月17日，我们已指定20万股首选股为A系列普通参与优先累积优先股，每股面值为$0.10，目前尚无股份发行。
B-1可转换优先股。 截至2024年7月31日，我们已将171,827.05股优先股指定为B-1可转换优先股，每股面值为0.10美元，其中171,827.05股为流通股。2024年10月17日，公司将所有未流通的B-1可转换优先股转换为B-2可转换优先股。因此，截至2024年10月17日，B-1可转换优先股没有流通的股份。
B-2可转换优先股。 截至2024年10月17日，我们已将175,263.58股优先股指定为B-2可转换优先股，每股面值为0.10美元，目前已发行175,263.58股。
Series B-2可转换优先股的指定。
Series b-2可转换优先股在公司普通股股权支付分红和公司清算、解散或清算时的资产分配方面优先。截至2024年10月17日，Series b-2可转换优先股的清算优先权为187,158,719.17美元。持有Series b-2可转换优先股的持有人将有权获得按年率为9.00%，每季度复利支付的累积分红（“分红”），或按年率为7.75%，每季度复利支付，由公司选定的支付方式。分红率可能根据某些事件的发生而增加或减少，如合同条款所述。公司在任何一季度选择不支付现金分红的情况下，有关一股Series b-2可转换优先股的分红将成为该股的清算优先权的一部分，如合同条款所述。此外，除非在宣布和支付该等普通股股份的分红或其他分配时，同时在Series b-2可转换优先股上宣布和支付相等的分红或分配（“参与分红”），否则不会在普通股上宣布或支付任何分红或其他分配，前提是在这种现金形式的任何分红情况下，代替现金支付，该参与分红将成为Series b-2可转换优先股的股份的清算优先权的一部分，如合同条款所述。根据合同条款中规定的某些事件，持有Series b-2可转换优先股的持有人将有权选择要求公司以现金形式支付分红（在法律允许的范围内）。
转换权利和强制赎回。
系列 B-2 可转换优先股可以在持有者的选择下随时转换为普通股。自2027年7月22日起，公司有权根据普通股在前30个连续交易日的价格，要求转换系列 B-2 可转换优先股，需遵循某些限制。系列 B-2 可转换优先股的转换价格为2024年10月17日的7.99美元，受到《指定证书》中规定的某些调整的影响（经调整后的"转换价格"）。
投票和同意权利。
系列b-2可转换优先股的持有者有权以转换后的基础与普通股的持有者投票。系列b-2可转换优先股的持有者有权就以下事项进行单独类别投票，包括但不限于对公司组织文件的修订，若这些修订对系列b-2可转换优先股产生不利影响，以及对公司的证券（不包括在合格发行中发行最多50,000,000股普通股）的授权或发行、分红支付、关联方交易、公司的证券回购或赎回、业务或资产处置、债务的产生和对公司现有信贷设施（“信贷设施”）的修订，而这些修订的条款和条件整体上（A）明显不同于现有信贷设施或（B）对公司履行与可选回购系列b-2可转换优先股有关的义务的能力产生不利影响，所有这些均须遵守在指定证书中列出的例外和资格。
Repurchase Rights.
Each holder of Series B-2 Convertible Preferred Stock will have the right to require the Company to repurchase its shares of Series B-2 Convertible Preferred Stock either (a) upon the consummation of an Asset Sale (as defined in the Certificate of Designations) meeting certain criteria, (b) following a CA Satisfaction (as defined in the Certificate of Designations), April 30, 2027 or (c) in all other cases, on or after October 31, 2028, in each case, at a price and on the terms set forth in the Certificate of Designations. The Company will have the right to repurchase all, or less than all, of the shares of Series B-1 Convertible Preferred Stock upon the consummation of an Asset Sale meeting the same criteria as clause (a) above, at a price and on the terms set forth in the Certificate of Designations.
In addition, each holder of Series B-2 Convertible Preferred Stock will have the right to cause the Company to repurchase its shares of Series B-2 Convertible Preferred Stock in connection with a Change of Control (as defined in the Certificate of Designations), at a price and on the terms set forth in the Certificate of Designations.
Right to Nominate Director.
For so long as the initial investors (the “Investors”) (or their permitted transferees) own beneficially and of record an amount of Series B-2 Convertible Preferred Stock with an aggregate liquidation preference equal to at least $25,000,000 (including the liquidation preference of any shares of Series B-2 Convertible Preferred Stock previously held that were subsequently converted into shares of common stock for so long as the Investors (or their permitted transferees) continue to own beneficially and of record such shares of common stock), the Investors representing at least a majority of the outstanding shares of Series B-2 Convertible Preferred Stock then outstanding have the right to nominate one person to serve on the Board of Directors (such nominee, the “Convertible Preferred Stock Nominee”, and such director, the “Convertible Preferred Stock Director”). For so long as the right to nominate one person to serve on the Board of Directors continues to be satisfied based on conditions outlined above, the Company shall nominate the Convertible Preferred Stock Nominee for election (or re-election, as applicable) as a director at the end of each term of the Convertible Preferred Stock Director as part of the slate proposed by the Company that is included in the proxy statement (or consent solicitation or similar document) of the Company relating to the election of the Board of Directors.
Standstill.
Until the earliest to occur of (a) January 22, 2025, with respect to clause (2) below and, otherwise, January 22, 2026, (b) the occurrence of an Insolvency Proceeding (as defined in the Credit Facility) and (c) certain Events of Default (as defined in the Credit Facility), subject to certain qualifications, the Investors will be subject to certain standstill restrictions pursuant to which the Investors will be restricted, among other things and subject to certain customary exceptions, from (1) acquiring more than a specified amount of the Company’s outstanding common stock or securities exchangeable for or convertible into the common stock, (2) entering into any derivative or other convertible instruments, hedging contracts or other derivative securities or similar instruments related to the purchase or sale of common stock, (3) making, participating in or encouraging any proxy solicitation or submitting any shareholder proposal to the Company, (4) publicly proposing any change of control or other material transaction involving the Company, (5) encouraging or entering into any agreements with any person with respect to any of the foregoing, (6) purchasing, selling or otherwise trading debt securities of the Company if as a result such Investor would beneficially own 19.99% of the Company’s outstanding debt securities or (7) taking any action that would require the Company to make a public announcement regarding any of the foregoing.
Transfer Restrictions.
Until the earlier of (a) January 22, 2025 and (b) termination of the standstill provisions (as described above), the Investors will be restricted from transferring the Series B-2 Convertible Preferred Stock, subject to certain specified exceptions.
Warrants
As of the date of this prospectus, we have outstanding 1,435,884 Warrants (the “Warrants”) to purchase an aggregate of 1,435,884 shares of common stock.
Duration and Exercise
The Warrants will have an exercise price of $0.10 per share of common stock and are exercisable at any time and from time to time on or prior to the close of business on June 17, 2031. The Warrants are exercisable, at the election of the holder, either in full or in part, for cash or by Net Share Settlement. The exercise price is subject to adjustment in connection with (i) stock splits, dividends or distributions or other similar transactions, (ii) the issuance of rights or warrants to holders of the common stock, and (iii) any distributions of assets, including cash, stock or other assets or property, to holders of the common stock.
Liquidity Event
In connection with any recapitalization, reorganization, reclassification, consolidation, merger, or other transaction, which, in each case, is effected in such a way that all of the holders of common stock are entitled to receive consideration with respect to or in exchange for common stock (other than a transaction that triggers an adjustment) (a “Liquidity Event”), each Warrant holder will have the right to receive, upon exercise of such Warrants, such consideration as would have been issued or payable in such Liquidity Event (if such Warrant holder had exercised such Warrant immediately prior to such Liquidity Event) with respect to or in exchange, as applicable, for the number of common stock that would have been issued upon exercise of such Warrants, if such Warrants had been exercised immediately prior to the occurrence of such Liquidity Event.
Repurchase Right
Upon a refinancing resulting in the payment in full of all relevant obligations on or before the relevant maturity date, each holder shall have the right (a “Put Right”) to sell, and, upon exercise by any holder of its Put Right, the Company shall have the obligation to purchase for cash, up to 50% of the Warrants held by such holder at a price per share equal to 90% of the 30-day volume-weighted average price of the common stock calculated as of the date of exercise of the Put Right.
Transferability
In accordance with the terms of the Warrants and subject to certain registration requirements, a Warrant may be transferred at the option of the holder.
Fractional Shares
No fractional Warrant Shares, or scrip of any fractional Warrant Shares, will be issued upon the exercise of the Warrants. If any fraction of a share of common stock be issuable on the exercise of any Warrant, the holder will be entitled to receive a cash payment equal to the Market Price (as defined in the Warrant) less the exercise price of such fractional share.
Trading Market
There is no established trading market for the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrant will be limited.
Rights as a Shareholder
Except as otherwise provided in the Warrants or by virtue of the holders’ ownership of shares of common stock, the holders of Warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until such Warrant holders exercise their warrants.
Registration Rights
Pursuant to the terms of the Warrants, we agreed to file a registration statement providing for the resale by the Selling Stockholders of the Warrant Shares within 30 calendar days from the date of the issuance of the Warrants. We agreed to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable thereafter and to keep such registration statement continuously effective until the earlier of (1) the date that the respective Selling Stockholder no longer owns any Warrants or Warrant Shares and (2) the date on which all Warrant Shares held by a holder may be sold pursuant to Rule 144 without regard to any volume or manner of sale restrictions, assuming all Warrants held by such holder are exercised on a Net Share Settlement basis.
Certain Provisions of Delaware Law
We are subject to the provisions of Section 203 of the DGCL, an anti-takeover law. In general, this statute provides that, except in certain limited circumstances, a corporation shall not engage in any “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, for purposes of Section 203 of the DGCL, an “interested stockholder” is a person who, together with affiliates, owns, or within three years did own, 15% or more of the corporation’s voting stock. This provision could have the effect of delaying or preventing a change in control of the Company.
Liability of Directors and Officers
As permitted by Delaware law, our charter contains a provision that eliminates the personal liability of the directors to us and our stockholders for monetary damages for breaches of fiduciary duties as directors, except that such provision does not apply to any breach that involves:
•a breach of a director’s duty of loyalty to the Company ;
•any act or omission not in good faith or which involves intentional misconduct or a knowing violation of law;
•a transaction from which the director derives an improper personal benefit; or
•the payment of dividends or the approval of stock repurchases or redemptions that are unlawful under the DGCL.
Our by-laws provide that we shall indemnify (a) any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that he is or was one of our directors, officers or employees, or is or was serving at our request as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement, actually and reasonably incurred by him or her in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was illegal, and (b) any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by us or in our name to procure a judgment in its favor by reason of the fact that he or she is or was one of our directors, officers or employees, or is or was serving at our request as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by him or her in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable for negligence or misconduct in the performance of his or her duty to us unless and only to the extent that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of Delaware or such other court shall deem proper.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the issuer pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.